FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207036602> ?p ?o ?g. }

• W4207036602 endingPage "225" @default.
• W4207036602 startingPage "216" @default.
• W4207036602 abstract "The anti-tumor activity and acceptable tolerability of pyrotinib plus chemotherapy have been demonstrated in phase III trials in human epidermal growth factor receptor 2-positive metastatic breast cancer (BC). In this study, we assessed the efficacy and safety of neoadjuvant pyrotinib plus trastuzumab and albumin-bound paclitaxel in women with human epidermal growth factor receptor 2-positive early or locally advanced BC.In this single-arm exploratory phase II trial, patients with untreated human epidermal growth factor receptor 2-positive BC (stage IIA-IIIC) received pyrotinib 400 mg once daily, trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg once a week, and albumin-bound paclitaxel 125 mg/m2 once a week for four 21-day cycles before surgery. The primary endpoint of the study was total pathological complete response (pCR) rate, defined as no microscopic invasive tumor remnants in the breast and axillary lymph nodes. The secondary endpoints were investigator-assessed objective response rate (ORR) and adverse event profiles.Between May 17, 2019 and November 26, 2019, a total of 21 patients were enrolled. The total pCR rate was 57.1% (12/21), whereas 23.8% (5/21) and 19.0% (4/21) of patients had minimal and moderate residual disease (RD), respectively. The ORR reached 100% (21/21) at the end of the neoadjuvant therapy. Grade ≥3 treatment-related adverse events were observed in 42.9% (9/21) of patients, including decreased neutrophil count [7 (33.3%)], diarrhoea [6 (28.6%)], decreased white blood cell count [5 (23.8%)], and vomiting [2 (9.5%)]. Adverse event-related dose reduction and interruption of pyrotinib occurred in 6 (28.6%) and 11 (52.4%) patients, respectively.In women with human epidermal growth factor receptor 2-positive early or locally advanced BC, neoadjuvant pyrotinib plus trastuzumab and albumin-bound paclitaxel effectively promoted total pCR rate with an acceptable safety profile (ClinicalTrials.gov, NCT04152057)." @default.
• W4207036602 created "2022-01-26" @default.
• W4207036602 creator A5000051451 @default.
• W4207036602 creator A5002892634 @default.
• W4207036602 creator A5008757468 @default.
• W4207036602 creator A5010479652 @default.
• W4207036602 creator A5013881064 @default.
• W4207036602 creator A5017090255 @default.
• W4207036602 creator A5022113905 @default.
• W4207036602 creator A5031234710 @default.
• W4207036602 creator A5036867616 @default.
• W4207036602 creator A5039007950 @default.
• W4207036602 creator A5040205022 @default.
• W4207036602 creator A5054927824 @default.
• W4207036602 creator A5059240782 @default.
• W4207036602 creator A5059987933 @default.
• W4207036602 creator A5063022734 @default.
• W4207036602 creator A5064369996 @default.
• W4207036602 creator A5071477102 @default.
• W4207036602 creator A5075276302 @default.
• W4207036602 date "2022-01-01" @default.
• W4207036602 modified "2023-09-26" @default.
• W4207036602 title "Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial" @default.
• W4207036602 cites W1987326983 @default.
• W4207036602 cites W2060597541 @default.
• W4207036602 cites W2096145980 @default.
• W4207036602 cites W2111578514 @default.
• W4207036602 cites W2151262170 @default.
• W4207036602 cites W2155560234 @default.
• W4207036602 cites W2222638000 @default.
• W4207036602 cites W2264815585 @default.
• W4207036602 cites W2318605753 @default.
• W4207036602 cites W2379981061 @default.
• W4207036602 cites W2521963431 @default.
• W4207036602 cites W2577651608 @default.
• W4207036602 cites W2611671407 @default.
• W4207036602 cites W2613098450 @default.
• W4207036602 cites W2802207314 @default.
• W4207036602 cites W2807467842 @default.
• W4207036602 cites W2810971819 @default.
• W4207036602 cites W2895039135 @default.
• W4207036602 cites W2896084151 @default.
• W4207036602 cites W2897683782 @default.
• W4207036602 cites W2945384827 @default.
• W4207036602 cites W2947067095 @default.
• W4207036602 cites W2954662492 @default.
• W4207036602 cites W2981669117 @default.
• W4207036602 cites W2985724618 @default.
• W4207036602 cites W3021411361 @default.
• W4207036602 cites W3056304265 @default.
• W4207036602 cites W3090147133 @default.
• W4207036602 cites W3127064904 @default.
• W4207036602 doi "https://doi.org/10.21037/gs-21-911" @default.
• W4207036602 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35242683" @default.
• W4207036602 hasPublicationYear "2022" @default.
• W4207036602 type Work @default.
• W4207036602 citedByCount "5" @default.
• W4207036602 countsByYear W42070366022022 @default.
• W4207036602 countsByYear W42070366022023 @default.
• W4207036602 crossrefType "journal-article" @default.
• W4207036602 hasAuthorship W4207036602A5000051451 @default.
• W4207036602 hasAuthorship W4207036602A5002892634 @default.
• W4207036602 hasAuthorship W4207036602A5008757468 @default.
• W4207036602 hasAuthorship W4207036602A5010479652 @default.
• W4207036602 hasAuthorship W4207036602A5013881064 @default.
• W4207036602 hasAuthorship W4207036602A5017090255 @default.
• W4207036602 hasAuthorship W4207036602A5022113905 @default.
• W4207036602 hasAuthorship W4207036602A5031234710 @default.
• W4207036602 hasAuthorship W4207036602A5036867616 @default.
• W4207036602 hasAuthorship W4207036602A5039007950 @default.
• W4207036602 hasAuthorship W4207036602A5040205022 @default.
• W4207036602 hasAuthorship W4207036602A5054927824 @default.
• W4207036602 hasAuthorship W4207036602A5059240782 @default.
• W4207036602 hasAuthorship W4207036602A5059987933 @default.
• W4207036602 hasAuthorship W4207036602A5063022734 @default.
• W4207036602 hasAuthorship W4207036602A5064369996 @default.
• W4207036602 hasAuthorship W4207036602A5071477102 @default.
• W4207036602 hasAuthorship W4207036602A5075276302 @default.
• W4207036602 hasBestOaLocation W42070366021 @default.
• W4207036602 hasConcept C121608353 @default.
• W4207036602 hasConcept C126322002 @default.
• W4207036602 hasConcept C143998085 @default.
• W4207036602 hasConcept C197934379 @default.
• W4207036602 hasConcept C203092338 @default.
• W4207036602 hasConcept C2776694085 @default.
• W4207036602 hasConcept C2777292972 @default.
• W4207036602 hasConcept C2778292576 @default.
• W4207036602 hasConcept C2778375690 @default.
• W4207036602 hasConcept C2779786085 @default.
• W4207036602 hasConcept C2779984678 @default.
• W4207036602 hasConcept C31760486 @default.
• W4207036602 hasConcept C530470458 @default.
• W4207036602 hasConcept C535046627 @default.
• W4207036602 hasConcept C71924100 @default.
• W4207036602 hasConcept C90924648 @default.
• W4207036602 hasConceptScore W4207036602C121608353 @default.
• W4207036602 hasConceptScore W4207036602C126322002 @default.
• W4207036602 hasConceptScore W4207036602C143998085 @default.

• next